Buprenorphine: What you know for certain that just ain’t so | Andrea Rubinstein, MD
There exist a vast amount of misinformation and misunderstanding about buprenorphine in clinical practice. Most of the ideas held about buprenoprhine actins are not backed up by data. In some cases the misinformation is 180 degrees wrong and impacts the care of our patients.
PRICE/PURCHASE -- $50
You must sign in or register register on this site before purchasing using the link on the upper right corner of this page. Only after registering will you see the "Add to Cart" button. To purchase, scroll to the bottom of the page and click "Add to Cart."
PHYSICIANS: The California Society of Addiction Medicine (CSAM) is accredited by the Institute for Medical Quality/California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.
CSAM designates this live educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™ Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 0.75 AMA/PRA Category 1 Credits™ for completing the Review Course.
Continuing education credit is also available for nurses, psychologists, pharmacists, physician assistants, therapists, and drug abuse counselors.
- Addiction medicine specialists who want an overview of the latest developments in the field and their relevance to clinical practice
- Primary care clinicians who want to get a better understanding of addiction and manage patients with addictions in their practice
- Public health officials who want an understanding of the current state of addiction treatment
- Non-physicians who are involved in the treatment of addiction
- Review what we know about buprenoprhine
- Dispel common myths and misconceptions about buprenrophine
- Explore some novel approaches to buprenophine and areas for future research
Andrea Rubinstein, MD, Chief, Department of Chronic Pain, Department of Anesthesiology and Research Chair, Kaiser Santa Rosa Medical Center, Assistant Clinical professor of Family and Community Medicine, UC San Francisco
Dr. Rubinstein has no relevant financial relationships to disclose.
|Sharone Abramowitz, MD||No relevant financial Relationship to disclose|
|Anthony Albanese, MD, FASAM||No relevant financial Relationship to disclose|
|Chwen-Yuen (Angie) Chen, MD||No relevant financial Relationship to disclose|
|Helen Py Driscoll, MD||No relevant financial Relationship to disclose|
|Murtuza Ghadiali, MD||No relevant financial Relationship to disclose|
|Anna Lembke, MD||No relevant financial Relationship to disclose|
|Claudia Landau, MD||No relevant financial Relationship to disclose|
|Jean Marsters, MD||No relevant financial Relationship to disclose|
|Thomas Meeks, MD||No relevant financial Relationship to disclose|
|Ingeborg Schafhalter-Zoppoth, MD||No relevant financial Relationship to disclose|
- 0.75 AMA Category 1